EGIS Pharmaceuticals PLC

The novel PREDYSTIC® Infliximab RA diagnostic test identifies bio-naïve patients with RA who are likely responders to infliximab treatment. The test is designed to use before treatment initiation, so it predicts drug response. This is a clinically validated blood test currently under CE-IVD registration.

EGIS is one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.